10-Q: RF Acquisition II Q3: Nanyang Biologics Merger, Extension Vote

RF Acquisition Corp II reports Q3 2025 results, detailing a proposed merger with Nanyang Biologics and a shareholder vote to extend its business combination deadline to August 2026.

Summary

• Reported net income of $1,056,869 for the three months ended September 30, 2025, and $3,153,849 for the nine months ended September 30, 2025.
• Entered into a definitive Business Combination Agreement on October 2, 2025, with NYB Holdings Limited (PubCo), NYB Pte. Ltd. (Amalgamation Sub), and Nanyang Biologics Pte. Ltd. (Nanyang).
• The Business Combination involves RF Acquisition Corp II merging into PubCo, followed by Amalgamation Sub and Nanyang amalgamating, with Nanyang becoming a wholly-owned subsidiary of PubCo.
• Shareholders will vote on November 10, 2025, on proposals to amend the Company's Charter and Trust Agreement to extend the Business Combination Period from November 15, 2025, to August 15, 2026, through up to nine one-month extensions.
• Each one-month extension requires an Extension Payment of $0.03 per unredeemed Public Share, up to a maximum of $60,000.
• Management has determined that conditions raise substantial doubt about the Company's ability to continue as a going concern within one year.
• Cash held in the Trust Account was $122,872,409 as of September 30, 2025.
• Current cash outside the Trust Account was $562,225 as of September 30, 2025, with a working capital of $64,578.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While a definitive business combination agreement has been reached, which is a positive step for a SPAC, the company faces a going concern warning and requires a shareholder-approved extension to its operating period. The positive interest income is offset by operational losses and the inherent uncertainties of completing a SPAC transaction.

Positives

• Secured a definitive Business Combination Agreement with Nanyang Biologics Pte. Ltd., a significant step for a SPAC.
• Generated substantial interest income from cash held in the Trust Account: $1,286,531 for Q3 2025 and $3,778,478 for the nine months ended September 30, 2025.
• The Sponsor has agreed to waive its rights to liquidating distributions from the Trust Account with respect to Founder Shares if a Business Combination is not completed, protecting public shareholder value.

Negatives

• Net income for Q3 2025 ($1,056,869) was lower than Q3 2024 ($1,422,951), primarily due to lower interest earned on cash held in the Trust Account.
• Incurred operating and formation costs of $229,662 for Q3 2025 and $624,629 for the nine months ended September 30, 2025, resulting in losses from operations.
• Management has identified conditions that raise substantial doubt about the Company's ability to continue as a going concern within one year.
• Disclosure controls and procedures were deemed not effective at a reasonable assurance level as of September 30, 2025.
• Accumulated deficit increased to $(3,960,774) as of September 30, 2025, from $(3,336,145) as of December 31, 2024.

Risks

• Inability to successfully effect a Business Combination within the Combination Period, which currently ends November 15, 2025, without an extension.
• Insufficient funds available to operate the business prior to the initial Business Combination if cost estimates are less than actual amounts needed.
• Potential need to obtain additional financing to complete the Business Combination or if a significant number of public shares are redeemed.
• Inability to obtain additional financing on commercially acceptable terms, if at all, which could lead to conservation measures or liquidation.
• Geopolitical instability (Russia-Ukraine, Israel-Hamas conflicts) could lead to market disruptions, volatility, supply chain interruptions, and increased cyber-attacks, adversely affecting the search for a Business Combination.
• The Sponsor's liability to indemnify the Trust Account for third-party claims (with exceptions) if funds fall below the redemption value per Public Share.
• Holders of rights will not receive any funds from the Trust Account and their rights will expire worthless if the Company fails to complete an initial Business Combination and liquidates.
• Comparison of financial statements with other public companies may be difficult due to the Company's election as an emerging growth company not to opt out of the extended transition period for new accounting standards.

Future Outlook

The Company intends to focus its search for a Business Combination on businesses in Asia within the deep technology sector, including artificial intelligence, quantum computing, and biotechnology, explicitly excluding entities with China operations through a VIE structure. It does not expect to generate operating revenues until after the completion of a Business Combination. Shareholders will vote on November 10, 2025, to extend the Business Combination deadline to August 15, 2026. The Company may need to obtain additional financing to complete the Business Combination or if a significant number of public shares are redeemed, and its officers, directors, and Sponsor may provide loans, though they are not obligated to do so.

Management Comments

• Management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of the Private Placement Units, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination.
• We do not believe we will need to raise additional funds in order to meet the expenditures required for operating our business.
• Management has determined that these conditions raise substantial doubt about our ability to continue as a going concern within one year after the date that the unaudited financial statements are issued.

Industry Context

RF Acquisition Corp II operates as a Special Purpose Acquisition Company (SPAC), a vehicle designed to raise capital through an IPO to acquire an existing company. Its stated focus on the 'deep technology sector' in Asia, encompassing artificial intelligence, quantum computing, and biotechnology, aligns with high-growth, innovation-driven investment themes. The proposed merger with Nanyang Biologics, a Singaporean biotechnology company, indicates a strategic move within its target industry. The need for an extension to complete a business combination is a common occurrence in the SPAC market, reflecting the complexities of identifying, valuing, and closing deals within tight regulatory timelines, especially in specialized sectors or during periods of market volatility.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• The Sponsor received 2,875,000 ordinary shares in exchange for $25,000 paid for operating costs on February 15, 2024.
• The Sponsor and EarlyBirdCapital, Inc. (EBC) purchased 400,000 Private Placement Units at $10.00 per unit, and an additional 37,500 Private Placement Units upon the underwriters' over-allotment exercise.
• The Sponsor has advanced $138,550 to the Company for certain operating costs, which is due on demand and non-interest bearing.
• The Sponsor charges the Company an administrative fee of up to $10,000 per month for office, utilities, and administrative support, with $165,000 accrued and unpaid as of September 30, 2025.
• The Sponsor has agreed to waive its rights to liquidating distributions from the Trust Account with respect to Founder Shares if the Company fails to complete a Business Combination.
• The Sponsor or its affiliates may loan the Company funds as Working Capital Loans, up to $1,500,000, which may be convertible into Working Capital Units.

Stakeholder Impact

• Shareholders: Will vote on the extension of the Business Combination Period, directly impacting the timeline and potential outcome of their investment. Public shareholders have redemption rights, which provide a floor to their investment value if the Business Combination is not completed or if they choose to redeem.
• Holders of Rights: Their rights will expire worthless if the Company liquidates without completing a Business Combination, as they are not entitled to funds from the Trust Account.
• Sponsor: Has significant financial exposure through Founder Shares and Private Placement Units, and provides ongoing financial and administrative support. Its waiver of liquidation rights on Founder Shares aligns its interests with public shareholders regarding the Trust Account.
• Nanyang Biologics: The target company, whose shareholders will exchange their shares for PubCo shares, becoming part of a publicly traded entity.
• Creditors: The Trust Account is generally protected from third-party claims, but the Company has obligations under Cayman Islands law to provide for creditor claims upon liquidation.

Next Steps

• Hold an extraordinary general meeting on November 10, 2025, for shareholders to vote on proposals to extend the Business Combination Period.
• If approved, proceed with the Business Combination with Nanyang Biologics, involving a merger with PubCo and subsequent amalgamation.
• If the extension is approved, make monthly Extension Payments of $0.03 per unredeemed Public Share to maintain the Trust Account.
• If the Business Combination is not completed within the extended Combination Period, cease operations, redeem 100% of the Public Shares, and liquidate the Company.

Key Dates

Recommendation

The company has made a significant step by entering into a definitive Business Combination Agreement with Nanyang Biologics, which is a positive development for a SPAC. However, the filing also highlights a 'going concern' warning and the necessity of a shareholder vote to extend the Business Combination Period. These factors introduce considerable uncertainty regarding the company's future. Investors should hold their position to await the outcome of the extension vote and further details on the Nanyang Biologics merger. The potential for redemption at NAV provides a downside protection, but the ultimate upside depends on the successful completion of the merger and the performance of the combined entity.

Keywords

SPAC, Business Combination, Nanyang Biologics, Deep Technology, Artificial Intelligence, Quantum Computing, Biotechnology, SEC Filing, 10-Q, Merger, Trust Account, Shareholder Vote, Extension, Going Concern, Financial Results, Asia